PTEN-deficient metastatic hormone-sensitive prostate cancer | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

110,847 results for “PTEN-deficient metastatic hormone-sensitive prostate cancer”

Trials

View all 90755 →

Active, not recruiting

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

1,012 participants · First posted Jul 30, 2020

CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

192 participants · First posted Mar 12, 2024

Not yet recruiting

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

160 participants · First posted Nov 18, 2023

Drugs

View all 2592 →

autologous dendritic cell tumor vaccine (metastatic hormone refractory prostate cancer)

GMC-1

ET-1002

Organizations

View all 1366 →

Cardiff Oncology

United States

Arvinas

United States

PROSTATE LASER CENTER, PLLC

United States

News

View all 16134 →

Truqap plus Abiraterone and ADT Improves rPFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

CAPItello-281 Trial Shows Capivasertib Plus Abiraterone Maintains Quality of Life in PTEN-Deficient Prostate Cancer

Capivasertib Plus Abiraterone Extends Radiographic Progression-Free Survival in PTEN-Deficient mHSPC

Page 1 of 11085